Job title: Senior Director, Head of Product Development & Global Program Leader, Cell Therapy
Lan Cao is currently the Senior Director, Head of Product Development in the Translational Engine, Cell Therapy group at Takeda, focusing on product development for various cell therapy products, including CAR-T, iPSC-derived T cells, gamma-delta T cells, and CRSIPR gene editing. Lan has more than 10 years’ experience in the cell therapy field in pharmaceutical and biotech companies with increasing roles and responsibilities. Lan has been the key CMC leader in filing multiple INDs and BLAs for cell therapy products. Prior to joining Takeda, Lan was the Executive Director of Technical Operations at CRISPR Therapeutics (CRSP) overseeing the development and manufacturing of CRISPR edited cellular products. His time at CRSP was preceded by Unum Therapeutics (UMRX) and Battersea Biotech, both are clinical stage cell therapy biotech companies in which he was leading the process and analytical development of both viral vectors and T cell products. Prior to that, Lan worked as an Associate Director in Novartis, leading the process development of the first FDA approved CAR-T product, Kymriah. Lan received his Ph.D. in Chemical Engineering from the University of Washington, and postdoctoral training at Harvard University, Bioengineering.
Industry Leaders Fireside Chat: Pipeline Progress: Get Your Questions on the Pipelines of the Leading Allogeneic Developers Answered 9:00 am
day: Day One